A landmark lawsuit is challenging the patents Myriad Genetics holds on the so-called breast cancer genes — patents that make Myriad the sole provider of a crucial genetic test. Do patents on genes spur research and innovation, or harm patients? Two experts share their views.
Kevin Noonan, patent attorney, molecular biologist, partner, McDonnell, Boehnen, Hulbert & Berghoff, LLP, Chicago, Ill.
Daniel Ravicher, executive director, Public Patent Foundation, lecturer in law and associate director, Intellectual Property Law Program, Benjamin N. Cardozo School of Law, New York, N.Y.